Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

HIV Mutations Can both Reduce and Enhance Virological Response to Boosted Darunavir (Prezista)

Development of viral resistance to anti-HIV drugs is a potential barrier to long-term treatment success. In the current study, published ahead of print in the January 15, 2009 online edition of the Journal of Antimicrobial Chemotherapy, French researchers sought to identify a pattern of HIV protease gene mutations associated with virological response to regimens containing ritonavir-boosted darunavir (Prezista).

Read more:

Changes in Darunavir (Prezista) Resistance Score after Previous Failure of Boosted Tipranavir (Aptivus) in Multidrug-resistant HIV Patients

Darunavir (Prezista) and tipranavir (Aptivus) are the most recently-approved protease inhibitors. Boosted with low-dose ritonavir (Norvir), they both exhibit activity against multidrug-resistant strains of HIV. However, researchers have not yet clearly defined the optimal sequencing of these 2 antiretroviral agents when used in salvage regimens for highly treatment-experienced patients [1,2].

Read more:

HIV9: More Data Demonstrate Similar Efficacy of Abacavir and Tenofovir

As previously reported, ACTG study 5202 was partially halted this past March after interim results showed that among treatment-naive patients with a high baseline HIV viral load (> 100,000 copies/mL), abacavir/lamivudine (the drugs in the Epzicom coformulation pill) did not suppress HIV as well as tenofovir/emtricitabine (the drugs in the Truvada pill) when both were used in combination with either efavirenz (Sustiva) or ritonavir-boosted atazanavir (Reyataz). Four cohort studies presented at the recent 9th International Congress on Drug Therapy in HIV Infection in Glasgow provided further evidence regarding the relative efficacy of the abacavir/lamivudine and tenofovir/emtricitabine backbones. 

Read more:

A Review of HIV Monotherapy with Ritonavir-boosted Protease Inhibitors

There is increasing interest in the simplification of combination antiretroviral therapy in order to lower pill burden, improve convenience, and reduce the costs of HIV treatment.

Read more:

HIV9: Atripla Users May Be Able to Take Weekend Treatment Breaks

In an effort to alleviate the inconvenience and other drawbacks of life-long daily treatment, many patients with HIV wish to take "drug holidays," or periodic breaks from antiretroviral therapy.

Read more: